In recent years, the idea of merging 3D printing with print electronics has become an area of both interest and skepticism. It is feasible, or is it just a gimmick? As the CEO of nScrypt, Ken Church set out to prove that it’s not only feasible, but applicable and relevant. In order to do this, the team at nScrypt is designing and manufacturing industrial printers that will be capable of producing the products we use everyday. But that’s not all, they are also printing biological materials such as collagen and red blood cells. This will pave the way for the printing of more complex tissues and organs, and will relieve biologists of the technological burden of the printing process and the software that’s behind it.  Most recently, nScrypt has began working with a new startup that’s using pancreatic cells to create spheroids, a biologic drug that has already shown to lower blood sugar levels in mice from 600 to 120 when administered subcutaneously. Church discusses a variety of topics, including thermoplastics in 3D printing, the steps involved and the challenges to overcome in printing organs, and nScrypt’s plan to have careful experiments conducted on the bioprinter in the international space station, which is set to launch February 2019.  Tune in for all the details, and visit www.nscrypt.com to learn more.